Needham & Company LLC Issues Pessimistic Forecast for Alphatec (NASDAQ:ATEC) Stock Price

Alphatec (NASDAQ:ATEC - Get Free Report) had its price target reduced by analysts at Needham & Company LLC from $25.00 to $14.00 in a note issued to investors on Wednesday,Benzinga reports. The firm currently has a "buy" rating on the medical technology company's stock. Needham & Company LLC's target price points to a potential upside of 36.85% from the stock's previous close.

A number of other analysts have also commented on ATEC. Stifel Nicolaus decreased their price objective on Alphatec from $24.00 to $20.00 and set a "buy" rating for the company in a report on Monday, March 9th. Weiss Ratings reaffirmed a "sell (e+)" rating on shares of Alphatec in a research report on Friday, March 27th. Piper Sandler reaffirmed an "overweight" rating on shares of Alphatec in a research report on Wednesday, February 25th. Barclays increased their price target on Alphatec from $23.00 to $27.00 and gave the company an "overweight" rating in a research report on Wednesday, January 7th. Finally, HC Wainwright reaffirmed a "buy" rating and set a $24.00 price target on shares of Alphatec in a research report on Monday, January 12th. One research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, Alphatec presently has a consensus rating of "Moderate Buy" and a consensus price target of $22.09.

Alphatec Stock Performance

Shares of ATEC opened at $10.23 on Wednesday. The company has a debt-to-equity ratio of 40.35, a quick ratio of 1.28 and a current ratio of 2.06. The stock has a 50 day moving average price of $11.73 and a two-hundred day moving average price of $15.95. The firm has a market capitalization of $1.57 billion, a P/E ratio of -10.77 and a beta of 0.96. Alphatec has a 52 week low of $9.11 and a 52 week high of $23.29.

Alphatec (NASDAQ:ATEC - Get Free Report) last issued its quarterly earnings data on Tuesday, May 5th. The medical technology company reported ($0.22) EPS for the quarter, missing analysts' consensus estimates of ($0.01) by ($0.21). The business had revenue of $192.11 million during the quarter, compared to analysts' expectations of $197.51 million. The business's quarterly revenue was up 13.6% on a year-over-year basis. During the same period in the prior year, the company earned ($0.35) earnings per share. Equities analysts forecast that Alphatec will post -0.28 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Alphatec news, General Counsel Tyson Eliot Marshall sold 88,835 shares of the business's stock in a transaction on Thursday, March 5th. The stock was sold at an average price of $12.49, for a total value of $1,109,549.15. Following the sale, the general counsel directly owned 559,459 shares in the company, valued at $6,987,642.91. The trade was a 13.70% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, EVP David Sponsel sold 163,452 shares of the business's stock in a transaction on Wednesday, March 11th. The shares were sold at an average price of $12.52, for a total value of $2,046,419.04. Following the completion of the sale, the executive vice president owned 504,932 shares in the company, valued at approximately $6,321,748.64. The trade was a 24.45% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders sold 689,614 shares of company stock valued at $8,634,850. Insiders own 22.80% of the company's stock.

Institutional Trading of Alphatec

Several hedge funds have recently made changes to their positions in ATEC. Summit Securities Group LLC bought a new stake in shares of Alphatec in the first quarter valued at $29,000. Aster Capital Management DIFC Ltd bought a new stake in shares of Alphatec in the third quarter valued at $34,000. Osterweis Capital Management Inc. bought a new stake in shares of Alphatec in the second quarter valued at $37,000. Northwestern Mutual Wealth Management Co. raised its stake in shares of Alphatec by 157.1% in the fourth quarter. Northwestern Mutual Wealth Management Co. now owns 2,571 shares of the medical technology company's stock valued at $54,000 after buying an additional 1,571 shares during the period. Finally, China Universal Asset Management Co. Ltd. bought a new stake in shares of Alphatec in the third quarter valued at $73,000. 66.35% of the stock is currently owned by institutional investors.

Alphatec News Summary

Here are the key news stories impacting Alphatec this week:

• Positive Sentiment: Management reiterated a bullish 2026 operating outlook: forecasts roughly $882M in 2026 revenue while keeping adjusted EBITDA at $134M, signaling confidence in near‑term growth and profitability execution. Alphatec forecasts $882M 2026 revenue
• Positive Sentiment: Alphatec secured a new senior secured syndicated credit facility (improves liquidity and funding capacity for growth initiatives and working capital). This reduces refinancing risk and supports execution of the 2026 plan. Alphatec Establishes New Syndicated Credit Facility for Growth
• Positive Sentiment: On a per‑share basis the company reported break‑even EPS for Q1 versus expectations for a small loss, a material improvement from last year’s loss and evidence operating leverage is improving. Alphatec (ATEC) Reports Break-Even Earnings for Q1
• Positive Sentiment: Q1 gross margins remain strong (GAAP ~71%, non‑GAAP ~72%) and revenue grew ~13.6% YoY — constructive for long‑term margin expansion if top‑line momentum holds. ATEC Reports First Quarter Financial Results
• Neutral Sentiment: Full Q1 earnings call transcript provides color on product trends, backlog and margin drivers — worth reviewing for guidance detail and surgeon adoption commentary. Alphatec Q1 2026 Earnings Call Transcript
• Negative Sentiment: Q1 EPS missed the consensus (reported ($0.22) vs. est. ($0.01)) and revenue slightly missed estimates ($192.11M vs. $197.51M), which prompted selling pressure as investors punished the surprise miss. Alphatec Q1 Earnings and Results
• Negative Sentiment: A notable institutional position disclosed it trimmed/sold roughly $18M of Alphatec stock last quarter — and coverage noted the stock plunged ~20% after the earnings print, amplifying near‑term downside via forced or momentum selling. This Fund Disclosed Selling $18 Million in Alphatec

Alphatec Company Profile

Alphatec Holdings, Inc NASDAQ: ATEC is a medical technology company focused on the design, development and commercialization of products for the surgical correction of degenerative spinal conditions. The company's portfolio centers on interbody implants, biologics, fixation devices and surgical planning tools intended to improve patient outcomes in spinal fusion procedures. Alphatec's flagship offerings include customizable interbody cages, bone graft materials and specialized instrumentation designed for minimally invasive and open spinal surgeries.

Founded as Alphatec Spine in 1985 and rebranded as Alphatec Holdings in 2018, the company has grown from a single-product organization into a multi-platform innovator in the spine market.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.